ReviewImmunologic research2026
Decoding PANoptosis: Crosstalk of cell death pathways in immunity and inflammation.
Review in Immunologic research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PANoptosis is an emerging regulated cell death that integrates the molecular machinery of apoptosis, necroptosis, and pyroptosis into a combined, highly coordinated process. Defined as a distinct, integrative form of cell death, PANoptosis simultaneously engages these three pathways through a multiprotein scaffold known as the PANoptosome, ensuring robust elimination of infected, damaged, or transformed cells. Initially described in response to viral infections, PANoptosis is now recognized as a critical regulator of immune defense, inflammation, and tissue homeostasis, with broad implications for infectious diseases, cancer, autoimmune disorders, neurodegeneration, and ischemia-reperfusion injury. This review provides a comprehensive overview of the molecular composition of the PANoptosome, key triggers of PANoptosis, and its morphological and biochemical hallmarks. We further discuss its dual roles as both a protective and pathogenic mechanism, highlighting context-dependent contributions to host defense and disease progression. Finally, we examine therapeutic opportunities, including small-molecule inhibitors and gene-editing approaches, and outline current challenges, such as the identification of reliable biomarkers and the need for precision-targeted strategies. By integrating recent advances, this review highlights PANoptosis as a conceptual shift in cell death biology and a promising avenue for novel interventions in inflammation-driven diseases.
Indexed as
Identifiers
42362957What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.